Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Ecollan

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
Journal of the American College of Cardiology|December 20, 2014
Effect of prasugrel pre-treatment strategy in patients undergoing percutaneous coronary intervention for NSTEMI: the ACCOAST-PCI studyGilles Montalescot, Jean-Philippe Collet, Patrick Ecollan, et al.
Resuscitation|March 30, 2025
Prehospital antiplatelet therapy in patients with out-of-hospital cardiac arrest suspected of acute coronary syndromePierre Charleux, Juliette Chommeloux, Anthony Elhadad, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|July 4, 2018
Impact of age on the effect of pre-hospital P2Y12 receptor inhibition in primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: the ATLANTIC-Elderly analysisJean-Philippe Collet, Mathieu Kerneis, Benoit Lattuca, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|April 1, 2025
Pre-treatment with P2Y12 inhibitors in Acute Myocardial Infarction with Cardiogenic ShockAnthony Elhadad, David Sulman, Niki Procopi, et al.
International Journal of Cardiology|June 18, 2017
Pre-hospital ticagrelor in ST-segment elevation myocardial infarction in the French ATLANTIC populationGuillaume Cayla, Frédéric Lapostolle, Patrick Ecollan, et al.
Journal of the American College of Cardiology|April 23, 2016
Early Aldosterone Blockade in Acute Myocardial Infarction: The ALBATROSS Randomized Clinical TrialFarzin Beygui, Guillaume Cayla, Vincent Roule, et al.
Lancet (London, England)|August 23, 2011
Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trialGilles Montalescot, Uwe Zeymer, Johanne Silvain, et al.
JACC. Cardiovascular Interventions|February 23, 2010
Enoxaparin in primary and facilitated percutaneous coronary intervention A formal prospective nonrandomized substudy of the FINESSE trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events)Gilles Montalescot, Stephen G Ellis, Mark A de Belder, et al.
Circulation. Cardiovascular Interventions|February 10, 2012
Prehospital abciximab in ST-segment elevation myocardial infarction: results of the randomized, double-blind MISTRAL studyPatrick Ohlmann, Philippe Reydel, Laurent Jacquemin, et al.
JACC. Cardiovascular Interventions|October 24, 2009
1-year survival in a randomized trial of facilitated reperfusion: results from the FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trialStephen G Ellis, Michal Tendera, Mark A de Belder, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Journal of the American College of Cardiology|December 20, 2014
Effect of prasugrel pre-treatment strategy in patients undergoing percutaneous coronary intervention for NSTEMI: the ACCOAST-PCI studyGilles Montalescot, Jean-Philippe Collet, Patrick Ecollan, et al.
Resuscitation|March 30, 2025
Prehospital antiplatelet therapy in patients with out-of-hospital cardiac arrest suspected of acute coronary syndromePierre Charleux, Juliette Chommeloux, Anthony Elhadad, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|July 4, 2018
Impact of age on the effect of pre-hospital P2Y12 receptor inhibition in primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: the ATLANTIC-Elderly analysisJean-Philippe Collet, Mathieu Kerneis, Benoit Lattuca, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|April 1, 2025
Pre-treatment with P2Y12 inhibitors in Acute Myocardial Infarction with Cardiogenic ShockAnthony Elhadad, David Sulman, Niki Procopi, et al.
International Journal of Cardiology|June 18, 2017
Pre-hospital ticagrelor in ST-segment elevation myocardial infarction in the French ATLANTIC populationGuillaume Cayla, Frédéric Lapostolle, Patrick Ecollan, et al.
Journal of the American College of Cardiology|April 23, 2016
Early Aldosterone Blockade in Acute Myocardial Infarction: The ALBATROSS Randomized Clinical TrialFarzin Beygui, Guillaume Cayla, Vincent Roule, et al.
Lancet (London, England)|August 23, 2011
Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trialGilles Montalescot, Uwe Zeymer, Johanne Silvain, et al.
JACC. Cardiovascular Interventions|February 23, 2010
Enoxaparin in primary and facilitated percutaneous coronary intervention A formal prospective nonrandomized substudy of the FINESSE trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events)Gilles Montalescot, Stephen G Ellis, Mark A de Belder, et al.
Circulation. Cardiovascular Interventions|February 10, 2012
Prehospital abciximab in ST-segment elevation myocardial infarction: results of the randomized, double-blind MISTRAL studyPatrick Ohlmann, Philippe Reydel, Laurent Jacquemin, et al.
JACC. Cardiovascular Interventions|October 24, 2009
1-year survival in a randomized trial of facilitated reperfusion: results from the FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trialStephen G Ellis, Michal Tendera, Mark A de Belder, et al.
Pageof 5